Relevant bibliographies by topics / Platinum group. Antineoplastic agents

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Platinum group. Antineoplastic agents'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Platinum group. Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Platinum group. Antineoplastic agents"

1

Odularu, Ayodele T., Peter A. Ajibade, Johannes Z. Mbese, and Opeoluwa O. Oyedeji. "Developments in Platinum-Group Metals as Dual Antibacterial and Anticancer Agents." Journal of Chemistry 2019 (November 6, 2019): 1–18. http://dx.doi.org/10.1155/2019/5459461.

Full text
Abstract:
Platinum-group (PG) complexes have been used as antibacterial and anticancer agents since the discovery of cisplatin. The science world still requires improvement on these complexes because of multidrug and antineoplastic resistances. This review observes discoverers and history of these platinum-group metals (PGMs), as well as their beneficial applications. The focus of this study was biological applications of PGMs in relation to human health. Sandwich and half-sandwich PGM coordination compounds and their metal nanoparticles give improved results for biological activities by enhancing effic
APA, Harvard, Vancouver, ISO, and other styles
2

César, Bruno Nogueira, and Marcelino de Souza Durão Júnior. "Acute kidney injury in cancer patients." Revista da Associação Médica Brasileira 66, suppl 1 (2020): s25—s30. http://dx.doi.org/10.1590/1806-9282.66.s1.25.

Full text
Abstract:
SUMMARY The increasing prevalence of neoplasias is associated with new clinical challenges, one of which is acute kidney injury (AKI). In addition to possibly constituting a clinical emergency, kidney failure significantly interferes with the choice and continuation of antineoplastic therapy, with prognostic implications in cancer patients. Some types of neoplasia are more susceptible to AKI, such as multiple myeloma and renal carcinoma. In cancer patients, AKI can be divided into pre-renal, renal (intrinsic), and post-renal. Conventional platinum-based chemotherapy and new targeted therapy ag
APA, Harvard, Vancouver, ISO, and other styles
3

Azab, Belal, Anood Alassaf, Abdulrahman Abu-Humdan, et al. "Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study." Interdisciplinary Toxicology 12, no. 2 (2019): 93–97. http://dx.doi.org/10.2478/intox-2019-0011.

Full text
Abstract:
Abstract Cisplatin and carboplatin are integral parts of many antineoplastic management regimens. Both platinum analogues are potent DNA alkylating agents that robustly induce genomic instability and promote apoptosis in tumor cells. Although the mechanism of action of both drugs is similar, cisplatin appears to be more cytotoxic. In this study, the genotoxic potential of cisplatin and carboplatin was compared using chromosomal aberrations (CAs) and sister-chromatid exchange (SCE) assays in cultured human lymphocytes. Results showed that cisplatin and carboplatin induced a significant increase
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Lu, Sheng Nie, Chen Ren, Yanqin Li, and Dehua Wu. "The incidence, risk factors and outcomes of chemotherapy related acute kidney injury in China." Journal of Clinical Oncology 38, no. 15_suppl (2020): e24161-e24161. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24161.

Full text
Abstract:
e24161 Background: Nephrotoxicity of chemotherapeutic agents remains a significant complication limiting the efficacy of the treatment. However, comprehensive data on the epidemiology and outcomes of chemotherapy related acute kidney Injury in China is lacking. Methods: We conducted a nationwide cohort study of hospitalized patients from 25 general and children’s hospitals in China during 2013-2015. Patient-level data were obtained from the electronic hospitalization information system, prescription database and laboratory databases of all cancer patients who received chemotherapy and had at l
APA, Harvard, Vancouver, ISO, and other styles
5

Bakalova, Adriana G., Rossen T. Buyukliev, Rositsa P. Nikolova, Boris L. Shivachev, Rositsa A. Mihaylova, and Spiro M. Konstantinov. "Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin." Anti-Cancer Agents in Medicinal Chemistry 19, no. 10 (2019): 1243–52. http://dx.doi.org/10.2174/1871520619666190214103345.

Full text
Abstract:
Background: The accidental discovery of Cisplatin’s growth-inhibiting properties a few decades ago led to the resurgence of interest in metal-based chemotherapeutics. A number of well-discussed factors such as severe systemic toxicity and unfavourable physicochemical properties further limit the clinical application of the platinating agents. Great efforts have been undertaken in the development of alternative platinum derivatives with an extended antitumor spectrum and amended toxicity profile as compared to the reference drug cisplatin. The rational design of conventional platinum analogues
APA, Harvard, Vancouver, ISO, and other styles
6

Markman, Maurie. "Toxicities of the platinum antineoplastic agents." Expert Opinion on Drug Safety 2, no. 6 (2003): 597–607. http://dx.doi.org/10.1517/14740338.2.6.597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Makrilia, Nektaria, Ekaterini Syrigou, Ioannis Kaklamanos, Leonidas Manolopoulos, and Muhammad Wasif Saif. "Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review." Metal-Based Drugs 2010 (September 20, 2010): 1–11. http://dx.doi.org/10.1155/2010/207084.

Full text
Abstract:
Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications
APA, Harvard, Vancouver, ISO, and other styles
8

Fanelli, Mirco, Mauro Formica, Vieri Fusi, Luca Giorgi, Mauro Micheloni, and Paola Paoli. "New trends in platinum and palladium complexes as antineoplastic agents." Coordination Chemistry Reviews 310 (March 2016): 41–79. http://dx.doi.org/10.1016/j.ccr.2015.11.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bakhonsky, Vladyslav V., Aleksander A. Pashenko, Jonathan Becker, et al. "Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(ii) complexes." Dalton Transactions 49, no. 40 (2020): 14009–16. http://dx.doi.org/10.1039/d0dt02391d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text
Abstract:
Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Platinum group. Antineoplastic agents"

1

Flynn, Allison. "Transition metals as anti-tumoral agents : some structure-function relationships of the platinum group metals /." Master's thesis, This resource online, 1994. http://scholar.lib.vt.edu/theses/available/etd-03022010-020016/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dewa, Shaliza Zaini. "Novel 3,3-dialkyldiaziridine platinum and palladium complexes." Thesis, University of Sussex, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oosthuizen, Lukas Marthinus. "New platinum coordination compounds : their synthesis, characterization and anticancer application." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1018795.

Full text
Abstract:
The aim of this thesis was to investigate the properties of novel platinum compounds with possible potential as anticancer agents, and to determine how their behaviour could lead to a better understanding of the chemistry involved. The final criteria were improvement of their anticancer behaviour. Since many questions are still unanswered as to the role of sulfur in anticancer action, studies were undertaken to synthesize novel platinum(II) complexes having non-leaving groups consisting of a combination of an aromatic nitrogen and thioetherial sulfur capable of forming a five membered ring upo
APA, Harvard, Vancouver, ISO, and other styles
4

Jaganath, Yatish. "Advances in platinum-amine chemotherapeutic agents : their chemistry and applicationc." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1021222.

Full text
Abstract:
The research conducted in this study focussed on advancing the knowledge database of diamineplatinum complexes on two frontiers: 1) the development of novel anticancer complexes, and 2) improvements in their synthetic chemistry. Novel square-planar dichloro and oxalato platinum(II) complexes were synthesized as potential anticancer agents in accordance with a comprehensive set of factors identified as being significant in optimizing such action. The nonleaving ligands consisted of asymmetric chelating chiral diamines of the form 1- (1-R-imidazol-2yl)(R')methanamine (R representing methyl, buty
APA, Harvard, Vancouver, ISO, and other styles
5

McCandless, Stewart Grant. "The synthesis of some novel 1,2,3-benzotriazine-platinum complexes with potential antineoplastic activity." Thesis, Heriot-Watt University, 1988. http://hdl.handle.net/10399/999.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wang, Xinghao, and 王星昊. "Platinum on the road: the activation and transport of novel platinum anticancer drugs by the extracellulardomain of human copper transporter I (HCTR1)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48199205.

Full text
Abstract:
Platinum-based anticancer drugs such as cisplatin, carboplatin and nedaplatin have been widely used in the chemotherapy of a variety of solid tumours for several decades. However, the development of both inherent and acquired resistance has greatly limited the efficacy of all of these drugs. Several mechanisms were proposed to explain the cellular resistance to these platinum drugs, including decreased drug accumulation. Previously, it was suggested that cisplatin enters cells via passive diffusion, followed by intracellular hydrolysis and activation prior to targeting DNA. However, re
APA, Harvard, Vancouver, ISO, and other styles
7

Yachnin, Jeffrey R. "Chemical, pharmacokinetic and biological aspects of platinum-based drugs /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-221-7/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Phelps, Jennifer Suzanne 1960. "CISPLATIN NEPHROTOXICITY: IN VITRO STUDIES (KIDNEY, TOXICOLOGY, PLATINUM)." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/291243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bouwer, Yolanda. "Novel aspects of platinum-amine coordination compounds: their chemistry and anticancer application." Thesis, Nelson Mandela Metropolitan University, 2008. http://hdl.handle.net/10948/d1021052.

Full text
Abstract:
The aim in this thesis, was to synthesize novel platinum coordination compounds, in order to develop compounds with improved anticancer action which could lead to an improved understanding of the mechanism by which they operate and at the same time, improve synthetic methods for their products. The initial work included the development of a novel synthetic method for 1R,2R-diaminocyclohexaneoxalato-platinum(II) (oxaliplatin), by using an essentially non-aqueous solvent medium and direct ligand exchange at elevated temperatures. This was done by a study of the kinetics of the reaction in a vari
APA, Harvard, Vancouver, ISO, and other styles
10

Myburgh, Jolanda. "Synthesis and characterization of novel platinum complexes : their anticancer behaviour." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1018621.

Full text
Abstract:
In this dissertation novel non-leaving groups were employed to synthesize platinum complexes which can contribute to the understanding or improvement of anticancer action. These complexes basically consist of (NS)-chelate and amineplatinum complexes. Bidentate (NS)-donor ligands were used as non-leaving ligands in the syntheses of platinum(II) complexes with iodide, chloride, bromide and oxalate anions as leaving groups. These complexes were synthesized and studied since many questions regarding the interaction of sulfur donors and platinum still exists. These relate to thermodynamic and kinet
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Platinum group. Antineoplastic agents"

1

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

M, Pinedo H., and Schornagel J. H, eds. Platinum and other metal coordination compounds in cancer chemotherapy 2. Plenum Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Meeting, National Cancer Institute (U S. ). Cancer Therapy Evaluation Program Investigational Drug Branch Phase I. Working Group. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, November 14-15, 1985. Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

National Cancer Institute (U.S.). Cancer Therapy Evaluation Program. Investigational Drug Branch. Phase I Working Group. Meeting. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, November 17-18, 1986. Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Meeting, National Cancer Institute (U S. ). Cancer Therapy Evaluation Program Investigational Drug Branch Phase I. Working Group. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, July 8-9, 1986. Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine: Carboplatine: symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Libbey Eurotext, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Marino, Nicolini, ed. Platinum and other metal coordination compounds in cancer chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Nijhoff, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. Humana Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. Humana Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sciences), Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity (1986 Pontifical Academy of. Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity, October 21-25, 1986. Pontificia Academia Scientiarvm ; Schenectady, N.Y. : Adenine Press [distributor], 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Platinum group. Antineoplastic agents"

1

Bruder, Beatrice, Clare L. S. Wiseman, and Fathi Zereini. "Solubility of Emitted Platinum Group Elements (Pt, Pd and Rh) in Airborne Particulate Matter (PM10) in the Presence of Organic Complexing Agents." In Environmental Science and Engineering. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44559-4_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Taber, Douglass F. "The Krische Synthesis of Bryostatin 7." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0090.

Full text
Abstract:
The bryostatins, as exemplified by bryostatin 75, are an exciting class of natural products. In addition to being effective antineoplastic agents, they show activity against Alzheimer’s disease. The central ring-forming step in the synthesis of 5 reported (J. Am. Chem. Soc. 2011, 133, 13876) by Michael J. Krische of the University of Texas, Austin is the triply convergent coupling of the chirons 1 and 2 with the linchpin reagent 3. The preparation of 1 and of 2 showcases the hydrogen transfer strategy for carbon–carbon bond construction developed by the Krische group. The synthesis of 2 began with the previously described double coupling of the simple starting materials 6 and 7. The product diol 8 had >99% ee. Ozonolysis of 8 was followed by a reductive coupling with the allene, which installed the gem dimethyl substituents of 2, and also the third oxygenated stereogenic center. The preparation of 1 proceeded from the aldehyde 10, prepared by Sharpless asymmetric dihydroxylation of 3-pentenenitrile. The chelate-controlled addition of propargyl zinc 11 led to the alkyne 12. Reductive coupling of the alkyne of 12 with the aldehyde of 13, again following a Krische procedure, delivered 1. The triply convergent Keck-Yu condensation of 1 with 3, and then with 2, gave, after some manipulation, the desired tetrahydropyran 4. Selective hydrolysis of the methyl ester in the presence of the acetates followed by selective silylation of two of the three secondary hydroxyls gave a suitable substrate for Yamaguchi cyclization to give 14. Selective oxidative cleavage of two of the three alkenes then gave an intermediate keto aldehyde that was carried on to bryostatin 7 5 following known procedures. The key to the synthesis of the complex bryostatin 7 5 was the ready supply of the chirons 1 and 2, prepared by the simple but powerful enantioselective reductive couplings developed by the Krische group. These couplings will have many other applications in target-directed synthesis.
APA, Harvard, Vancouver, ISO, and other styles
3

Taber, Douglass F. "Stereoselective C–O Ring Construction: The Keck Synthesis of Bryostatin I." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0046.

Full text
Abstract:
Vladimir Gevorgyan of the University of Illinois, Chicago homologated (Angew. Chem. Int. Ed. 2011, 50, 2808) the ketone 1 to the epoxide 2 using cyanogen bromide. Manabu Abe of Hiroshima University optimized (J. Am. Chem. Soc. 2011, 133, 2592) the diastereoselectivity of the Paternò-Büchi addition of benzophenone 4 to the secondary allylic alcohol 3 to give 5. Debaraj Mukherjee of the Indian Institute of Integrative Medicine constructed (Org. Lett. 2011, 13, 576) the lactone 7 by adding acetate to 6, with remarkable regioselectivity and diastereoselectivity. Tristan H. Lambert of Columbia University employed (Org. Lett. 2011, 13, 740) cyclopropenium activation to cyclize the diol 8 to 9. Brian L. Pagenkopf of the University of Western Ontario designed (Org. Lett. 2011, 13, 572) a Co catalyst for the diastereoselective oxidative cyclization of 11 to 12. Goverdhan Mehta of the Indian Institute of Science, Bangalore, found (Tetrahedron Lett. 2011, 52, 1749) that the Z-diene 13 cyclized efficiently to give the cyclic ether 14. Fabien Gagosz of the Ecole Polytechnique found (J. Am. Chem. Soc. 2011, 133, 7696) that the protonated complex derived from the allene 15 abstracted a hydride from the distal benzyl group, leading to cyclization to 16. Haruhiko Fuwa of Tohoku University found (Org. Lett. 2011, 13, 1820) that the unsaturated thioester 17 cyclized under gentle acid catalysis. Unsaturated esters (not illustrated) can be cyclized under alkaline conditions (Tetrahedron Lett. 2011, 52, 1372). Malcolm D. McLeod of the Australian National University established (J. Org. Chem. 2011, 76, 1992) a combination of Escherichia coli-derived enzyme and an α-d-glucuronyl fluoride donor for converting an alcohol 19 to the corresponding glucuronide metabolite 20. En route to an improved synthesis of the schweinfurthins, potent antineoplastic agents, David F. Wiemer of the University of Iowa devised (J. Org. Chem. 2011, 76, 909) the cyclization/ benzyloxymethyl transfer cascade that transformed 21 into 22. The synthesis and biological activity of the bryostatins is developing into one of the great success stories of natural products chemistry. A key step in the total synthesis of bryostatin 1 25 designed (J. Am. Chem. Soc. 2011, 133, 744) by Gary E. Keck of the University of Utah was the Rainier cyclization of 23 to 24.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Platinum group. Antineoplastic agents"

1

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, et al. "Epithelial Ovarian Cancer: Real-World Outcomes." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Full text
Abstract:
Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find f
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Platinum group. Antineoplastic agents' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography